Advertisement

Insulin-like Growth Factors and Kidney Disease

Published:August 21, 2014DOI:https://doi.org/10.1053/j.ajkd.2014.05.024
      Insulin-like growth factors (IGF-1 and IGF-2) are necessary for normal growth and development. They are related structurally to proinsulin and promote cell proliferation, differentiation, and survival, as well as insulin-like metabolic effects, in most cell types and tissues. In particular, IGFs are important for normal pre- and postnatal kidney development. IGF-1 mediates many growth hormone actions, and both growth hormone excess and deficiency are associated with perturbed kidney function. IGFs affect renal hemodynamics both directly and indirectly by interacting with the renin-angiotensin system. In addition to the IGF ligands, the IGF system includes receptors for IGF-1, IGF-2/mannose-6-phosphate, and insulin, and a family of 6 high-affinity IGF-binding proteins that modulate IGF action. Disordered regulation of the IGF system has been implicated in a number of kidney diseases. IGF activity is enhanced in early diabetic nephropathy and polycystic kidneys, whereas IGF resistance is found in chronic kidney failure. IGFs have a potential role in enhancing stem cell repair of kidney injury. Most IGF actions are mediated by the tyrosine kinase IGF-1 receptor, and inhibitors recently have been developed. Further studies are needed to determine the optimal role of IGF-based therapies in kidney disease.

      Index Words

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Clemmons D.R.
        Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.
        Nat Rev Drug Discov. 2007; 6: 821-833
        • Denley A.
        • Cosgrove L.J.
        • Booker G.W.
        • Wallace J.C.
        • Forbes B.E.
        Molecular interactions of the IGF system.
        Cytokine Growth Factor Rev. 2005; 16: 421-439
        • Bach L.A.
        • Headey S.J.
        • Norton R.S.
        IGF-binding proteins—the pieces are falling into place.
        Trends Endocrinol Metab. 2005; 16: 228-234
        • Bach L.A.
        The insulin-like growth factor system in kidney disease and hypertension.
        Curr Opin Nephrol Hypertens. 2012; 21: 86-91
        • Ward A.
        Beckwith-Wiedemann syndrome and Wilms' tumour.
        Mol Hum Reprod. 1997; 3: 157-168
        • Rogers S.A.
        • Ryan G.
        • Hammerman M.R.
        Insulin-like growth factors I and II are produced in the metanephros and are required for growth and development in vitro.
        J.Cell Biol. 1991; 113: 1447-1453
        • Matsell D.G.
        • Delhanty P.J.
        • Stepaniuk O.
        • Goodyear C.
        • Han V.K.
        Expression of insulin-like growth factor and binding protein genes during nephrogenesis.
        Kidney Int. 1994; 46: 1031-1042
        • Price G.J.
        • Berka J.L.
        • Edmonson S.R.
        • Werther G.A.
        • Bach L.A.
        Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in rat kidney.
        Kidney Int. 1995; 48: 402-411
        • Rabkin R.
        • Schaefer F.
        New concepts: growth hormone, insulin-like growth factor-I and the kidney.
        Growth Horm IGF Res. 2004; 14: 270-276
        • Lindenbergh-Kortleve D.J.
        • Rosato R.R.
        • van Neck J.W.
        • et al.
        Gene expression of the insulin-like growth factor system during mouse kidney development.
        Mol Cell Endocrinol. 1997; 132: 81-91
        • Lupu F.
        • Terwilliger J.D.
        • Lee K.
        • Segre G.V.
        • Efstratiadis A.
        Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth.
        Dev Biol. 2001; 229: 141-162
        • Moerth C.
        • Schneider M.R.
        • Renner-Mueller I.
        • et al.
        Postnatally elevated levels of insulin-like growth factor (IGF)-II fail to rescue the dwarfism of IGF-I-deficient mice except kidney weight.
        Endocrinology. 2007; 148: 441-451
        • Rogers S.A.
        • Powell-Braxton L.
        • Hammerman M.R.
        Insulin-like growth factor I regulates renal development in rodents.
        Dev Genet. 1999; 24: 293-298
        • Wolf E.
        • Kramer R.
        • Blum W.F.
        • Foll J.
        • Brem G.
        Consequences of postnatally elevated insulin-like growth factor-II in transgenic mice: endocrine changes and effects on body and organ growth.
        Endocrinology. 1994; 135: 1877-1886
        • Mathews L.S.
        • Hammer R.E.
        • Behringer R.R.
        • et al.
        Growth enhancement of transgenic mice expressing human insulin-like growth factor I.
        Endocrinology. 1989; 123: 2827-2833
        • Doi T.
        • Striker L.J.
        • Quaife C.
        • et al.
        Progressive glomerulosclerosis develops in transgenic mice chronically expressing growth hormone and growth hormone releasing factor but not in those expressing insulinlike growth factor-1.
        Am J Pathol. 1988; 131: 398-403
        • Salmon Jr., W.D.
        • Daughaday W.H.
        A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro.
        J Lab Clin Med. 1957; 49: 825-836
        • Ohlsson C.
        • Mohan S.
        • Sjogren K.
        • et al.
        The role of liver-derived insulin-like growth factor-I.
        Endocr Rev. 2009; 30: 494-535
        • Sjogren K.
        • Liu J.L.
        • Blad K.
        • et al.
        Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice.
        Proc Natl Acad Sci U S A. 1999; 96: 7088-7092
        • Svensson J.
        • Tivesten A.
        • Sjogren K.
        • et al.
        Liver-derived IGF-I regulates kidney size, sodium reabsorption, and renal IGF-II expression.
        J Endocrinol. 2007; 193: 359-366
        • Nordstrom S.M.
        • Tran J.L.
        • Sos B.C.
        • Wagner K.U.
        • Weiss E.J.
        Liver-derived IGF-I contributes to GH-dependent increases in lean mass and bone mineral density in mice with comparable levels of circulating GH.
        Mol Endocrinol. 2011; 25: 1223-1230
        • Doublier S.
        • Seurin D.
        • Fouqueray B.
        • et al.
        Glomerulosclerosis in mice transgenic for human insulin-like growth factor-binding protein-1.
        Kidney Int. 2000; 57: 2299-2307
        • Doublier S.
        • Amri K.
        • Seurin D.
        • et al.
        Overexpression of human insulin-like growth factor binding protein-1 in the mouse leads to nephron deficit.
        Pediatr Res. 2001; 49: 660-666
        • Hoeflich A.
        • Wu M.Y.
        • Mohan S.
        • et al.
        Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain.
        Endocrinology. 1999; 140: 5488-5496
        • Modric T.
        • Silha J.V.
        • Shi Z.D.
        • et al.
        Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.
        Endocrinology. 2001; 142: 1958-1967
        • Silha J.V.
        • Gui Y.T.
        • Mishra S.
        • Leckstrom A.
        • Cohen P.
        • Murphy L.J.
        Overexpression of Gly(56)/Gly(80)/Gly(81)-mutant insulin-like growth factor-binding protein-3 in transgenic mice.
        Endocrinology. 2005; 146: 1523-1531
        • Tripathi G.
        • Salih D.A.M.
        • Drozd A.C.
        • Cosgrove R.A.
        • Cobb L.J.
        • Pell J.M.
        IGF-independent effects of insulin-like growth factor binding protein-5 (IGFBP5) in vivo.
        FASEB J. 2009; 23: 2616-2626
        • Zhou R.
        • Flaswinkel H.
        • Schneider M.
        • et al.
        Insulin-like growth factor-binding protein-4 inhibits growth of the thymus in transgenic mice.
        J Mol Endocrinol. 2004; 32: 349-364
        • Hirschberg R.
        • Kopple J.D.
        Evidence that insulin-like growth factor I increases renal plasma flow and glomerular filtration rate in fasted rats.
        J Clin Invest. 1989; 83: 326-330
        • Hirschberg R.
        • Brunori G.
        • Kopple J.D.
        • Guler H.-P.
        Effects of insulin-like growth factor I on renal function in normal men.
        Kidney Int. 1993; 43: 387-397
        • Hirschberg R.
        • Kopple J.D.
        • Blantz R.C.
        • Tucker B.J.
        Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat.
        J Clin Invest. 1991; 87: 1200-1206
        • Tonshoff B.
        • Kaskel F.J.
        • Moore L.C.
        Effects of insulin-like growth factor I on the renal juxtamedullary microvasculature.
        Am J Physiol Cell Physiol. 1998; 43: F120-F128
        • Feld S.
        • Hirschberg R.
        Growth hormone, the insulin-like growth factor system, and the kidney.
        Endocr Rev. 1996; 17: 423-480
        • Kamenicky P.
        • Mazziotti G.
        • Lombes M.
        • Giustina A.
        • Chanson P.
        Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications.
        Endocr Rev. 2014; 35: 234-281
        • Nagasu H.
        • Satoh M.
        • Kuwabara A.
        • et al.
        Overexpression of klotho protein modulates uninephrectomy-induced compensatory renal hypertrophy by suppressing IGF-I signals.
        Biochem Biophys Res Commun. 2011; 407: 39-43
        • Hammerman M.R.
        • Miller S.B.
        The growth hormone insulin-like growth factor axis in kidney revisited.
        Am J Physiol. 1993; 265: F1-F14
        • Aron D.C.
        • Rosenzweig J.L.
        • Abboud H.E.
        Synthesis and binding of insulin-like growth factor I by human glomerular mesangial cells.
        J Clin Endocrinol Metab. 1989; 68: 585-591
        • Conti F.G.
        • Striker L.J.
        • Elliot S.J.
        • Andreani D.
        • Striker G.E.
        Synthesis and release of insulinlike growth factor I by mesangial cells in culture.
        Am J Physiol. 1988; 255: F1214-F1219
        • Conti F.G.
        • Striker L.J.
        • Lesniak M.A.
        • MacKay K.
        • Roth J.
        • Striker G.E.
        Studies on binding and mitogenic effect of insulin and insulin-like growth factor I in glomerular mesangial cells.
        Endocrinology. 1988; 122: 2788-2795
        • Lupia E.
        • Elliot S.J.
        • Lenz O.
        • et al.
        IGF-1 decreases collagen degradation in diabetic NOD mesangial cells: implications for diabetic nephropathy.
        Diabetes. 1999; 48: 1638-1644
        • Doi T.
        • Striker L.J.
        • Elliot S.J.
        • Conti F.G.
        • Striker G.E.
        Insulinlike growth factor-1 is a progression factor for human mesangial cells.
        Am J Pathol. 1989; 134: 395-404
        • Schreiber B.D.
        • Hughes M.L.
        • Groggel G.C.
        Insulin-like growth factor-1 stimulates production of mesangial cell matrix components.
        Clin Nephrol. 1995; 43: 368-374
        • Kang B.P.
        • Frencher S.
        • Reddy V.
        • Kessler A.
        • Malhotra A.
        • Meggs L.G.
        High glucose promotes mesangial cell apoptosis by oxidant-dependent mechanism.
        Am J Physiol Renal Physiol. 2003; 284: F455-F466
        • Kang B.P.
        • Urbonas A.
        • Baddoo A.
        • Baskin S.
        • Malhotra A.
        • Meggs L.G.
        IGF-1 inhibits the mitochondrial apoptosis program in mesangial cells exposed to high glucose.
        Ame J Physiol Renal Physiol. 2003; 285: F1013-F1024
        • Pagtalunan M.E.
        • Miller P.L.
        • Jumping-Eagle S.
        • et al.
        Podocyte loss and progressive glomerular injury in type II diabetes.
        J Clin Invest. 1997; 99: 342-348
        • Kim Y.H.
        • Goyal M.
        • Kurnit D.
        • et al.
        Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat.
        Kidney Int. 2001; 60: 957-968
        • Reddy G.R.
        • Pushpanathan M.J.
        • Ransom R.F.
        • et al.
        Identification of the glomerular podocyte as a target for growth hormone action.
        Endocrinology. 2007; 148: 2045-2055
        • Mohammed J.A.
        • Mok A.Y.
        • Parbtani A.
        • Matsell D.G.
        Increased expression of insulin-like growth factors in progressive glomerulonephritis of the MRL/lpr mouse.
        Lupus. 2003; 12: 584-590
        • Tack I.
        • Elliot S.J.
        • Potier M.
        • Rivera A.
        • Striker G.E.
        • Striker L.J.
        Autocrine activation of the IGF-I signaling pathway in mesangial cells isolated from diabetic NOD mice.
        Diabetes. 2002; 51: 182-188
        • Matsell D.G.
        • Bennett T.
        • Armstrong R.A.
        • Goodyer P.
        • Goodyer C.
        • Han V.K.
        Insulin-like growth factor (IGF) and IGF binding protein gene expression in multicystic renal dysplasia.
        J Am Soc Nephrol. 1997; 8: 85-94
        • Fujinaka H.
        • Katsuyama K.
        • Yamamoto K.
        • et al.
        Expression and localization of insulin-like growth factor binding proteins in normal and proteinuric kidney glomeruli.
        Nephrology (Carlton). 2010; 15: 700-709
        • Bridgewater D.J.
        • Dionne J.M.
        • Butt M.J.
        • Pin C.L.
        • Matsell D.G.
        The role of the type I insulin-like growth factor receptor (IGF-IR) in glomerular integrity.
        Growth Horm IGF Res. 2008; 18: 26-37
        • Bridgewater D.J.
        • Ho J.
        • Sauro V.
        • Matsell D.G.
        Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway.
        Kidney Int. 2005; 67: 1308-1314
        • Kamenicky P.
        • Viengchareun S.
        • Blanchard A.
        • et al.
        Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly.
        Endocrinology. 2008; 149: 3294-3305
        • Kamenicky P.
        • Blanchard A.
        • Frank M.
        • et al.
        Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.
        J Clin Endocrinol Metab. 2011; 96: 2127-2135
        • Kamenicky P.
        • Blanchard A.
        • Gauci C.
        • et al.
        Pathophysiology of renal calcium handling in acromegaly: what lies behind hypercalciuria?.
        J Clin Endocrinol Metab. 2012; 97: 2124-2133
        • Giustina A.
        • Bossoni S.
        • Cimino A.
        • Pizzocolo G.
        • Romanelli G.
        • Wehrenberg W.B.
        Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion.
        J Clin Endocrinol Metab. 1990; 71: 1486-1490
        • Giustina A.
        • Wehrenberg W.B.
        Growth hormone neuroregulation in diabetes mellitus.
        Trends Endocrinol Metab. 1994; 5: 73-78
        • Flyvbjerg A.
        Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease.
        Diabetologia. 2000; 43: 1205-1223
        • Flyvbjerg A.
        • Bornfeldt K.E.
        • Marshall S.M.
        • Arnqvist H.J.
        • Orskov H.
        Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats.
        Diabetologia. 1990; 33: 334-338
        • Bach L.A.
        • Jerums G.
        Effect of puberty on initial kidney growth and rise in kidney IGF-1 in diabetic rats.
        Diabetes. 1990; 39: 557-562
        • Flyvbjerg A.
        • Bennett W.F.
        • Rasch R.
        • Kopchick J.J.
        • Scarlett J.A.
        Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice.
        Diabetes. 1999; 48: 377-382
        • Landau D.
        • Segev Y.
        • Eshet R.
        • Flyvbjerg A.
        • Phillip M.
        Changes in the growth hormone-IGF-I axis in non-obese diabetic mice.
        Int J Exp Diabetes Res. 2000; 1: 9-18
        • Landau D.
        • Segev Y.
        • Afargan M.
        • et al.
        A novel somatostatin analogue prevents early renal complications in the nonobese diabetic mouse.
        Kidney Int. 2001; 60: 505-512
        • Segev Y.
        • Landau D.
        • Marbach M.
        • Shehadeh N.
        • Flyvbjerg A.
        • Phillip M.
        Renal hypertrophy in hyperglycemic non-obese diabetic mice is associated with persistent renal accumulation of insulin-like growth factor I.
        J Am Soc Nephrol. 1997; 8: 436-444
        • Bach L.A.
        • Stevenson J.L.
        • Allen T.J.
        • Jerums G.
        • Herington A.C.
        Kidney insulinlike growth factor-I mRNA levels are increased in postpubertal diabetic rats.
        J Endocrinol. 1991; 129: 5-10
        • Flyvbjerg A.
        • Kessler U.
        • Dorka B.
        • Funk B.
        • Orskov H.
        • Kiess W.
        Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats.
        Diabetologia. 1992; 35: 589-593
        • Bach L.A.
        • Cox A.J.
        • Mendelsohn F.A.O.
        • Herington A.C.
        • Werther G.A.
        • Jerums G.
        Focal induction of IGF-I binding proteins in proximal tubules of diabetic rat kidney.
        Diabetes. 1992; 41: 499-507
        • Landau D.
        • Chin E.
        • Bondy C.
        • et al.
        Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes.
        Endocrinology. 1995; 136: 1835-1842
        • Price G.J.
        • Berka J.L.
        • Werther G.A.
        • Bach L.A.
        Cell-specific regulation of mRNAs for IGF-I and IGF-binding proteins-4 and -5 in streptozotocin-diabetic rat kidney.
        J Mol Endocrinol. 1997; 18: 5-14
        • Werner H.
        • Shen-Orr Z.
        • Stannard B.
        • Burguera B.
        • Roberts Jr., C.T.
        • LeRoith D.
        Experimental diabetes increases insulinlike growth factor I and II receptor concentration and gene expression in kidney.
        Diabetes. 1990; 39: 1490-1497
        • Shinada M.
        • Akdeniz A.
        • Panagiotopoulos S.
        • Jerums G.
        • Bach L.A.
        Proteolysis of insulin-like growth factor-binding protein-3 is increased in urine from patients with diabetic nephropathy.
        J Clin Endocrinol Metab. 2000; 85: 1163-1169
        • Levin-Iaina N.
        • Iaina A.
        • Raz I.
        The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats.
        Diabetes Metab Res Rev. 2011; 27: 235-243
        • Bach L.A.
        • Dean R.
        • Youssef S.
        • Cooper M.E.
        Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy.
        Nephrol Dial Transplant. 2000; 15: 347-354
        • Gronbaek H.
        • Nielsen B.
        • Schrijvers B.
        • Vogel I.
        • Rasch R.
        • Flyvbjerg A.
        Inhibitory effects of octreotide on renal and glomerular growth in early experimental diabetes in mice.
        J Endocrinol. 2002; 172: 637-643
        • Bellush L.L.
        • Doublier S.
        • Holland A.N.
        • Striker L.J.
        • Striker G.E.
        • Kopchick J.J.
        Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice.
        Endocrinology. 2000; 141: 163-168
        • Cingel-Ristic V.
        • Schrijvers B.F.
        • van Vliet A.K.
        • et al.
        Kidney growth in normal and diabetic mice is not affected by human insulin-like growth factor binding protein-1 administration.
        Exp Biol Med. 2005; 230: 135-143
        • Serri O.
        • Beauregard H.
        • Brazeau P.
        • et al.
        Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes.
        JAMA. 1991; 265: 888-892
        • Mak R.H.
        • Cheung W.W.
        • Roberts Jr., C.T.
        The growth hormone-insulin-like growth factor-I axis in chronic kidney disease.
        Growth Horm IGF Res. 2008; 18: 17-25
        • Kaskel F.
        Chronic renal disease: a growing problem.
        Kidney Int. 2003; 64: 1141-1151
        • Mehls O.
        • Schaefer F.
        • Tonshoff B.
        • Wuhl E.
        Effectiveness of growth hormone treatment in short children with chronic renal failure.
        J Pediatr. 2002; 141: 147-148
        • Wuhl E.
        • Schaefer F.
        Effects of growth hormone in patients with chronic renal failure: experience in children and adults.
        Horm Res. 2002; 58: 35-38
        • Tonshoff B.
        • Blum W.F.
        • Wingen A.M.
        • Mehls O.
        Serum insulin-like growth factors (IGFs) and IGF binding proteins 1, 2, and 3 in children with chronic renal failure: relationship to height and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood.
        J Clin Endocrinol Metab. 1995; 80: 2684-2691
        • Ulinski T.
        • Mohan S.
        • Kiepe D.
        • et al.
        Serum insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 in children with chronic renal failure: relationship to growth and glomerular filtration rate. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. German Study Group for Growth Hormone Treatment in Chronic Renal Failure.
        Pediatr Nephrol. 2000; 14: 589-597
        • Powell D.R.
        • Liu F.
        • Baker B.K.
        • et al.
        Insulin-like growth factor-binding protein-6 levels are elevated in serum of children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group.
        J Clin Endocrinol Metab. 1997; 82: 2978-2984
        • Powell D.R.
        • Liu F.
        • Baker B.K.
        • et al.
        Effect of chronic renal failure and growth hormone therapy on the insulin-like growth factors and their binding proteins.
        Pediatr Nephrol. 2000; 14: 579-583
        • Tonshoff B.
        • Powell D.R.
        • Zhao D.
        • et al.
        Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia.
        Endocrinology. 1997; 138: 938-946
        • Woelfle J.
        • Billiard J.
        • Rotwein P.
        Acute control of insulin-like growth factor-I gene transcription by growth hormone through Stat5b.
        J Biol Chem. 2003; 278: 22696-22702
        • Sun D.F.
        • Zheng Z.
        • Tummala P.
        • Oh J.
        • Schaefer F.
        • Rabkin R.
        Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle.
        J Am Soc Nephrol. 2004; 15: 2630-2636
        • Wang X.H.
        • Mitch W.E.
        Muscle wasting from kidney failure—a model for catabolic conditions.
        Int J Biochem Cell Biol. 2013; 45: 2230-2238
        • Tonshoff B.
        • Kiepe D.
        • Ciarmatori S.
        Growth hormone/insulin-like growth factor system in children with chronic renal failure.
        Pediatr Nephrol. 2005; 20: 279-289
        • Mahan J.D.
        • Warady B.A.
        • Consensus Committee
        Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement.
        Pediatr Nephrol. 2006; 21: 917-930
        • Feldt-Rasmussen B.
        • El Nahas M.
        Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor-1 in the management of chronic kidney disease.
        Semin Nephrol. 2009; 29: 50-58
        • Guebre-Egziabher F.
        • Juillard L.
        • Boirie Y.
        • Laville M.
        • Beaufrere B.
        • Fouque D.
        Short-term administration of a combination of recombinant growth hormone and insulin-like growth factor-I induces anabolism in maintenance hemodialysis.
        J Clin Endocrinol Metab. 2009; 94: 2299-2305
        • Lepenies J.
        • Wu Z.
        • Stewart P.M.
        • Strasburger C.J.
        • Quinkler M.
        IGF-1, IGFBP-3 and ALS in adult patients with chronic kidney disease.
        Growth Horm IGF Res. 2010; 20: 93-100
        • Jia T.
        • Gama Axelsson T.
        • Heimburger O.
        • et al.
        IGF-1 and survival in ESRD.
        Clin J Am Soc Nephrol. 2014; 9: 120-127
        • Miller S.B.
        • Martin D.R.
        • Kissane J.
        • Hammerman M.R.
        Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat.
        Proc Natl Acad Sci U S A. 1992; 89: 11876-11880
        • Hirschberg R.
        • Brunori G.
        • Kopple J.D.
        • Guler H.P.
        Effects of insulin-like growth factor I on renal function in normal men.
        Kidney Int. 1993; 43: 387-397
        • Franklin S.C.
        • Moulton M.
        • Sicard G.A.
        • Hammerman M.R.
        • Miller S.B.
        Insulin-like growth factor I preserves renal function postoperatively.
        Am J Physiol. 1997; 272: F257-F259
        • Hladunewich M.A.
        • Corrigan G.
        • Derby G.C.
        • et al.
        A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF.
        Kidney Int. 2003; 64: 593-602
        • Igarashi P.
        • Somlo S.
        Polycystic kidney disease.
        J Am Soc Nephrol. 2007; 18: 1371-1373
        • Song X.
        • Di Giovanni V.
        • He N.
        • et al.
        Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks.
        Hum Mol Genet. 2009; 18: 2328-2343
        • Liu C.
        • Zhang Y.
        • Yuan L.
        • Fu L.
        • Mei C.
        Rosiglitazone inhibits insulin-like growth factor 1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
        Mol Med Rep. 2013; 8: 861-864
        • Peters I.
        • Tossidou I.
        • Achenbach J.
        • et al.
        IGF-binding protein-3 modulates TGF-beta/BMP-signaling in glomerular podocytes.
        J Am Soc Nephrol. 2006; 17: 1644-1656
        • Worthmann K.
        • Peters I.
        • Kumpers P.
        • et al.
        Urinary excretion of IGFBP-1 and -3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease.
        Growth Factors. 2010; 28: 129-138
        • Tokunaga K.
        • Uto H.
        • Takami Y.
        • et al.
        Insulin-like growth factor binding protein-1 levels are increased in patients with IgA nephropathy.
        Biochem Biophys Res Commun. 2010; 399: 144-149
        • Pollak M.
        The insulin and insulin-like growth factor receptor family in neoplasia: an update.
        Nat Rev Cancer. 2012; 12: 159-169
        • Humphreys B.D.
        Kidney injury, stem cells and regeneration.
        Curr Opin Nephrol Hypertens. 2014; 23: 25-31
        • Imberti B.
        • Morigi M.
        • Tomasoni S.
        • et al.
        Insulin-like growth factor-1 sustains stem cell mediated renal repair.
        J Am Soc Nephrol. 2007; 18: 2921-2928
        • Xinaris C.
        • Morigi M.
        • Benedetti V.
        • et al.
        A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion.
        Cell Transplant. 2013; 22: 423-436
        • Tomasoni S.
        • Longaretti L.
        • Rota C.
        • et al.
        Transfer of growth factor receptor mRNA via exosomes unravels the regenerative effect of mesenchymal stem cells.
        Stem Cells Dev. 2013; 22: 772-780
        • Hale L.
        • Welsh G.
        • Perks C.
        • et al.
        Insulin-like growth factor-II is produced by, signals to, and is an important survival factor for the mature podocyte in man and mouse.
        J Pathol. 2013; 230: 95-106
        • Ivanova L.
        • Butt M.J.
        • Matsell D.G.
        Mesenchymal transition in kidney collecting duct epithelial cells.
        Am J Physiol Renal Physiol. 2008; 294: F1238-F1248
        • Chen D.
        • Chen Z.
        • Park C.
        • et al.
        Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms.
        Gene. 2013; 531: 23-30
        • New D.D.
        • Block K.
        • Bhandhari B.
        • Gorin Y.
        • Abboud H.E.
        IGF-I increases the expression of fibronectin by Nox4-dependent Akt phosphorylation in renal tubular epithelial cells.
        Am J Physiol Cell Physiol. 2012; 302: C122-C130
        • Luque V.
        • Escribano J.
        • Grote V.
        • et al.
        Does insulin-like growth factor-1 mediate protein-induced kidney growth in infants? A secondary analysis from a randomized controlled trial.
        Pediatr Res. 2013; 74: 223-229
        • Charlton J.R.
        • Norwood V.F.
        • Kiley S.C.
        • Gurka M.J.
        • Chevalier R.L.
        Evolution of the urinary proteome during human renal development and maturation: variations with gestational and postnatal age.
        Pediatr Res. 2012; 72: 179-185